Sanofi’s Sutimlimab Shows Promise In Rare Blood Disorder
First-In-Class Complement Pathway Inhibitor Impresses In Cold Agglutinin Disease
Executive Summary
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
You may also be interested in...
New Data Reinforces Potential Of Sanofi's Sutimlimab After Shock FDA Snub
Having suffered a setback last year when deficiencies at a third-party manufacturer scuppered hopes of a quick US approval of sutimlimab for cold agglutinin disease, Sanofi has released more promising data on its C1s inhibitor at the European Hematology Association meeting.
12 Approvals To Look Out For In Q4
The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker.
Seven Talking Points At ASH 2019
The tireless pace of change in hemato-oncology was showcased in Orlando.